The REVISE-Diabesity trial investigates the efficacy of the Endobarrier device in conjunction with Liraglutide for treating obesity and type 2 diabetes in patients unresponsive to conventional therapies. Given the rising prevalence of obesity and T2DM, this study addresses a significant unmet medical need, potentially positioning the Endobarrier as a viable non-surgical alternative to bariatric surgery. The outcomes could enhance market competitiveness against existing GLP-1 receptor agonists and other obesity treatments, while also informing future product development strategies. Stakeholders should consider the implications of successful results on market access, reimbursement strategies, and potential partnerships for commercialization.